Sixth Wave delivered a Discovery Affinity System
Sixth Wave will also be attending
In addition, Sixth Wave continued on-site technical assessments and business development activities
“We are pleased with the major advances, particularly at AESI, as they are critical to expanding our international resources in the current rollout of our Affinity systems. The early integration of the AESI engineers, sales and support team is going smoothly while we continue to work on servicing the existing customers. Our discussions with AESI and Retro once again confirm that the cleanability and operating parameters of the Affinity system will be valuable to the industry. Additional outreach from Sixth Wave in recent weeks has added three new potential clients to the list in both South and Australia
About the sixth wave
Sixth Wave is a nanotechnology company with patented technologies focused on the extraction and detection of target substances at the molecular level using highly specialized molecularly imprinted polymers (MIPs). The Company is in the process of commercializing its Affinity cannabinoid purification system, as well as IXOS, a line of extraction polymers for the gold mining industry. The Company is also in the development phase of a rapid diagnostic test for viruses called Accelerated MIPs (AMIPS).
Sixth Wave can design, develop and market MIP solutions for a wide range of industries. The Company is focused on nanotechnology architectures highly relevant to the detection and separation of viruses, biogenic amines and other pathogens for which the Company has products in various stages of development.
Telephone: (801) 582-0559
Email: [email protected]
This press release contains certain statements that may be deemed “forward-looking statements”, including possible statements regarding the planned use of the proceeds and performance of the IXOS, Affinity and AMIPs technologies. All statements in this press release, other than statements of historical fact, that address future events or developments that the Company expects are forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual events or developments may differ materially from those projected in the forward-looking statements. Such forward-looking statements inherently involve known and unknown risks and uncertainties that could cause the Company’s actual performance and financial results in future periods to differ materially from the projections of future performance or results expressed or implied by such forward-looking statements. In particular, the successful development and commercialization of the IXOS, Affinity or AMIPs technologies is subject to the risk of not proving successful, uncertainty of medical product development, uncertainty of timing or availability of required regulatory approvals, lack of track record of development of products for specific applications and the need for additional capital to carry out product development activities. The value of any products eventually developed could be adversely affected if patents are not granted. The company has not yet applied to any regulatory agency for regulatory approval for the use of this product.